No Data
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) equity distribution for the first three quarters of 2024: 1 yuan for every 10 shares, with the equity registration on January 9.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that the plan for equity distribution for the first three quarters of 2024 is as follows: to the public...
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) has obtained the high-tech enterprise certification.
Gelonghui December 31st丨Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that the company recently received the "High-tech Enterprise Certificate" issued jointly by the Zhejiang Provincial Department of Economy and Information Technology, the Zhejiang Provincial Department of Finance, and the State Administration of Taxation Zhejiang Provincial Taxation Bureau. The certificate number is GR202433011726, and it is valid for three years.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) has obtained registration certificates for three types of skin prick test allergenic extracts including sweet gum pollen.
Gelonghui reported on December 23 that Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that it has recently obtained the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration. The company submitted registration for three skin prick liquid products: "Sycamore Pollen Allergen Skin Prick Liquid," "German Cockroach Allergen Skin Prick Liquid," and "Cat Dander Allergen Skin Prick Liquid," which have been approved for market launch. The three skin prick liquid products, including the Sycamore Pollen Allergen Skin Prick Liquid, are related to the company's already launched "Dust Mite Skin Prick Diagnostic Kit" (National Drug Approval Number S20080010) and "House Dust Mite Skin Prick Diagnostic Kit."
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ): Received the clinical trial approval notification for the house dust mite membrane agent.
On December 16, Glonghui reported that Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) announced that the company obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration's online service hall. The clinical trial application for the "House Dust Mite Membrane Preparation" submitted by the company has been approved. The registration classification is a Class 1 Biological Product for therapeutic use. The indications are for specific immunotherapy for adult patients with allergic rhinitis related to dust mite sensitization (with or without allergic conjunctivitis, allergic asthma). After obtaining the "Drug Clinical Trial Approval Notice," the product will undergo Phase I, Phase II, and Phase III clinical trials.
Private Companies Invested in Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) Copped the Brunt of Last Week's CN¥372m Market Cap Decline
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) 29% Price Boost Is Out Of Tune With Earnings
